__symbol__ Stock Quote Price and Forecast
June 12, 2026
KARD Stock Quote Price and Forecast | CNN
-
KARD share price: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
-
KARD stock price change: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
-
KARD market open/close: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
-
KARD market cap: currently unavailable. Sorry, we currently don’t have enough data to create an insight.
Smart score
No recent TipRanks articles are available for KARD
-
KARD total revenue: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
-
KARD net income: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
-
KARD earnings per share: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
analyst rating
-
buy
-
hold
-
sell
1-year stock price forecast
$ Market cap
P/E ratio
$ Price
1d change
52-week range
-
How competitors are chosen
KARD’s competitors are included in the Health Technology sector and Biotechnology group
-
KARD market cap: currently unavailable. Sorry, we currently don’t have enough data to create an insight.
Search
RECENT PRESS RELEASES
Related Post
